Cargando…
Survival of soft tissue sarcoma patients after completing six cycles of first-line anthracycline containing treatment: an EORTC-STBSG database study
BACKGROUND: Doxorubicin based chemotherapy is standard first line treatment for patients with soft tissue sarcoma. Currently several options to improve survival after doxorubicin based chemotherapy are being studied. This study reports on survival after completing 6 cycles of doxorubicin containing...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7488114/ https://www.ncbi.nlm.nih.gov/pubmed/32944214 http://dx.doi.org/10.1186/s13569-020-00137-5 |
_version_ | 1783581628621127680 |
---|---|
author | Verschoor, Arie Jan Litière, Saskia Marréaud, Sandrine Judson, Ian Toulmonde, Maud Wardelmann, Eva LeCesne, Axel Gelderblom, Hans |
author_facet | Verschoor, Arie Jan Litière, Saskia Marréaud, Sandrine Judson, Ian Toulmonde, Maud Wardelmann, Eva LeCesne, Axel Gelderblom, Hans |
author_sort | Verschoor, Arie Jan |
collection | PubMed |
description | BACKGROUND: Doxorubicin based chemotherapy is standard first line treatment for patients with soft tissue sarcoma. Currently several options to improve survival after doxorubicin based chemotherapy are being studied. This study reports on survival after completing 6 cycles of doxorubicin containing first line treatment, which is important when designing studies trying to improve outcomes of first line treatment. METHODS: A retrospective database analysis was performed on 2045 patients from 12 EORTC sarcoma trials (inclusion period 1980–2012) receiving first line doxorubicin based chemotherapy for advanced soft tissue sarcoma in order to establish progression free survival and overall survival after completing 6 cycles of first line doxorubicin based chemotherapy. Endpoints were overall survival and progression free survival. Factors studied were histologic subtype and type of doxorubicin chemotherapy. RESULTS: 748 of 2045 (36.6%) received at least 6 cycles and did not progress during or at the end of chemotherapy. 475 of 2045 (23.2%) of patients received exactly 6 cycles and did not progress during or at the end of chemotherapy. Median progression free survival after 6 cycles of doxorubicin based chemotherapy was 4.2 months (95% confidence interval 3.7–4.8) and median overall survival 15.7 months (14.0–17.8). Median progression free survival and overall survival from randomisation/registration were 8.7 months (95% confidence interval 8.2–9.1) and 20.1 months (95% confidence interval 18.3–22.3) respectively. Significant differences in progression free survival were found between chemotherapy regimens, but not for overall survival. These data are also reported for patients receiving 7 or more cycles of chemotherapy and for patients with 3 or more cycles of chemotherapy. CONCLUSION: This large retrospective study is the first to report progression free survival and overall survival after completion of 6 cycles of first line doxorubicin containing chemotherapy. These results are important when designing new studies exploring for example maintenance therapy after doxorubicin based chemotherapy. |
format | Online Article Text |
id | pubmed-7488114 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-74881142020-09-16 Survival of soft tissue sarcoma patients after completing six cycles of first-line anthracycline containing treatment: an EORTC-STBSG database study Verschoor, Arie Jan Litière, Saskia Marréaud, Sandrine Judson, Ian Toulmonde, Maud Wardelmann, Eva LeCesne, Axel Gelderblom, Hans Clin Sarcoma Res Research BACKGROUND: Doxorubicin based chemotherapy is standard first line treatment for patients with soft tissue sarcoma. Currently several options to improve survival after doxorubicin based chemotherapy are being studied. This study reports on survival after completing 6 cycles of doxorubicin containing first line treatment, which is important when designing studies trying to improve outcomes of first line treatment. METHODS: A retrospective database analysis was performed on 2045 patients from 12 EORTC sarcoma trials (inclusion period 1980–2012) receiving first line doxorubicin based chemotherapy for advanced soft tissue sarcoma in order to establish progression free survival and overall survival after completing 6 cycles of first line doxorubicin based chemotherapy. Endpoints were overall survival and progression free survival. Factors studied were histologic subtype and type of doxorubicin chemotherapy. RESULTS: 748 of 2045 (36.6%) received at least 6 cycles and did not progress during or at the end of chemotherapy. 475 of 2045 (23.2%) of patients received exactly 6 cycles and did not progress during or at the end of chemotherapy. Median progression free survival after 6 cycles of doxorubicin based chemotherapy was 4.2 months (95% confidence interval 3.7–4.8) and median overall survival 15.7 months (14.0–17.8). Median progression free survival and overall survival from randomisation/registration were 8.7 months (95% confidence interval 8.2–9.1) and 20.1 months (95% confidence interval 18.3–22.3) respectively. Significant differences in progression free survival were found between chemotherapy regimens, but not for overall survival. These data are also reported for patients receiving 7 or more cycles of chemotherapy and for patients with 3 or more cycles of chemotherapy. CONCLUSION: This large retrospective study is the first to report progression free survival and overall survival after completion of 6 cycles of first line doxorubicin containing chemotherapy. These results are important when designing new studies exploring for example maintenance therapy after doxorubicin based chemotherapy. BioMed Central 2020-09-09 /pmc/articles/PMC7488114/ /pubmed/32944214 http://dx.doi.org/10.1186/s13569-020-00137-5 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Verschoor, Arie Jan Litière, Saskia Marréaud, Sandrine Judson, Ian Toulmonde, Maud Wardelmann, Eva LeCesne, Axel Gelderblom, Hans Survival of soft tissue sarcoma patients after completing six cycles of first-line anthracycline containing treatment: an EORTC-STBSG database study |
title | Survival of soft tissue sarcoma patients after completing six cycles of first-line anthracycline containing treatment: an EORTC-STBSG database study |
title_full | Survival of soft tissue sarcoma patients after completing six cycles of first-line anthracycline containing treatment: an EORTC-STBSG database study |
title_fullStr | Survival of soft tissue sarcoma patients after completing six cycles of first-line anthracycline containing treatment: an EORTC-STBSG database study |
title_full_unstemmed | Survival of soft tissue sarcoma patients after completing six cycles of first-line anthracycline containing treatment: an EORTC-STBSG database study |
title_short | Survival of soft tissue sarcoma patients after completing six cycles of first-line anthracycline containing treatment: an EORTC-STBSG database study |
title_sort | survival of soft tissue sarcoma patients after completing six cycles of first-line anthracycline containing treatment: an eortc-stbsg database study |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7488114/ https://www.ncbi.nlm.nih.gov/pubmed/32944214 http://dx.doi.org/10.1186/s13569-020-00137-5 |
work_keys_str_mv | AT verschoorariejan survivalofsofttissuesarcomapatientsaftercompletingsixcyclesoffirstlineanthracyclinecontainingtreatmentaneortcstbsgdatabasestudy AT litieresaskia survivalofsofttissuesarcomapatientsaftercompletingsixcyclesoffirstlineanthracyclinecontainingtreatmentaneortcstbsgdatabasestudy AT marreaudsandrine survivalofsofttissuesarcomapatientsaftercompletingsixcyclesoffirstlineanthracyclinecontainingtreatmentaneortcstbsgdatabasestudy AT judsonian survivalofsofttissuesarcomapatientsaftercompletingsixcyclesoffirstlineanthracyclinecontainingtreatmentaneortcstbsgdatabasestudy AT toulmondemaud survivalofsofttissuesarcomapatientsaftercompletingsixcyclesoffirstlineanthracyclinecontainingtreatmentaneortcstbsgdatabasestudy AT wardelmanneva survivalofsofttissuesarcomapatientsaftercompletingsixcyclesoffirstlineanthracyclinecontainingtreatmentaneortcstbsgdatabasestudy AT lecesneaxel survivalofsofttissuesarcomapatientsaftercompletingsixcyclesoffirstlineanthracyclinecontainingtreatmentaneortcstbsgdatabasestudy AT gelderblomhans survivalofsofttissuesarcomapatientsaftercompletingsixcyclesoffirstlineanthracyclinecontainingtreatmentaneortcstbsgdatabasestudy |